Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) EBITDA (2024 - 2025)

Historic EBITDA for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to -$80.0 million.

  • Kura Oncology's EBITDA fell 5143.78% to -$80.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$236.9 million, marking a year-over-year change of. This contributed to the annual value of -$171.9 million for FY2024, which is 1787.76% down from last year.
  • According to the latest figures from Q3 2025, Kura Oncology's EBITDA is -$80.0 million, which was down 5143.78% from -$72.7 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's EBITDA peaked at -$19.6 million during Q4 2024, and registered a low of -$80.0 million during Q3 2025.